Add to Favourites
To login click here
HeartBeam, Inc. has reported its financial and operational results for the second quarter of 2024, showcasing progress towards key clinical and regulatory milestones for its HeartBeam AIMIGo™ System. The company’s AIMIGo 510(k) submission, a credit card-sized, cable-free cardiac monitoring device, is currently being reviewed by the FDA and is expected to be the basis for future submissions. Additionally, HeartBeam has completed two pre-submission meetings with the FDA for its planned second 510(k) submission, which will focus on the algorithms that convert 360-degree signals into a synthesized 12-lead ECG.